Loading...
•
Dec 31, 2024
Nuwellis Q4 2024 Earnings Report
Nuwellis reported lower revenue and a net loss but improved operating efficiency in Q4 2024.
Key Takeaways
Nuwellis reported Q4 2024 revenue of $2.3 million, a 9% decline compared to the prior year. The company posted a net loss of $1.5 million, or $0.44 per share, with a 25% reduction in total operating expenses. The critical care segment saw revenue growth of 35%, while gross margin improved to 58.4%. Cash and cash equivalents stood at $5.1 million at year-end.
Revenue decreased by 9% to $2.3 million compared to Q4 2023.
Net loss improved to $1.5 million from $7.9 million in the prior year quarter.
Critical Care revenue segment grew by 35% year-over-year.
Gross margin improved to 58.4% from 54.4% in Q4 2023.
Nuwellis
Nuwellis
Forward Guidance
Nuwellis expects revenue growth opportunities driven by increased CMS reimbursement, market expansion, and operational efficiencies.
Positive Outlook
- CMS reimbursement for Aquadex therapy increased fourfold to $1,639.
- Consumables utilization increased by 21% in Q4 2024.
- Operating expense reduction of 25% supports financial sustainability.
- Critical Care segment remains a strong growth driver with 35% YoY increase.
- Expansion of outpatient accounts is expected to drive further revenue growth.
Challenges Ahead
- Overall revenue declined by 9% compared to the prior year.
- International and US console sales declined in Q4 2024.
- Company remains unprofitable despite cost-cutting measures.
- Lower R&D spending could impact future innovation efforts.
- Market penetration challenges remain despite improving financials.